Reference : Zolmitriptan (Zomig, 311c90), a Novel Dual Central and Peripheral 5ht1b/1d Agonist: A...
Scientific journals : Article
Human health sciences : Neurology
Social & behavioral sciences, psychology : Neurosciences & behavior
http://hdl.handle.net/2268/24502
Zolmitriptan (Zomig, 311c90), a Novel Dual Central and Peripheral 5ht1b/1d Agonist: An Overview of Efficacy
English
Schoenen, Jean mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie]
Sawyer, J. [> > > >]
Oct-1997
Cephalalgia : An International Journal of Headache
Blackwell Science
17
Suppl 18
28-40
Yes (verified by ORBi)
International
0333-1024
[en] The efficacy of zolmitriptan (Zomig, 311C90), a 5-hydroxytryptamine (5HT)1B/1D receptor agonist, in the acute oral treatment of migraine was evaluated in an extensive clinical trial program. Four randomized, placebo-controlled studies (total 2480 patients) were performed; data from two of these trials established that a 2.5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%). In this program, the efficacy of zolmitriptan was not influenced by the pretreatment headache duration; the presence of aura preceding the headache, migraine associated with menses or migraine upon awakening; or by concomitant use of oral contraceptives or antidepressants. In addition, zolmitriptan 5 mg proved consistently effective in the treatment of multiple migraine attacks for up to 1 year. Zolmitriptan reduced the incidence of nausea, photophobia and phonophobia, reduced impairment of normal activity and demonstrated positive effects on patients' quality of life. Thus, zolmitriptan is a highly effective acute oral antimigraine therapy, with 2.5 mg providing the optimal balance between efficacy and tolerability.
http://hdl.handle.net/2268/24502

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.